Jorge Castillo
Clinical Director, Bing Center for Waldenstrom Macroglobulinemia
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (28)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Approximately 20% of patients with Waldenström macroglobulinemia (WM) report family history (FH) of hematologic malignancies. However, the impact of FH on patient outcomes remains unclear. We included 1000 patients with WM to determine the relationship between FH, characteristics, complications, and treatment outcomes. Data collected included clinical features at diagnosis, complications (Bing-Neel syndrome [BNS], aggressive transformation, AL [light chain] amyloidosis, and neuropathy), FH cluster (WM [WM-FH], other B-cell FH [B-FH], non–B-cell FH [NON–B-FH], and sporadic [NO-FH]), and treatment outcomes. Logistic regression models were fitted to estimate the odds of complications. Time-to-event outcomes were assessed using the Kaplan-Meier method, and differences between groups evaluated using the log-rank test. Proportional hazards Cox regression models were fitted to determine the impact of WM-FH on time to first treatment (TTFT), overall survival (OS), and survival after first treatment initiation (SAFTI). The NO-FH group was the reference group for the regression analyses. The median follow-up time from diagnosis was 13 years. There were more women in the WM-FH than in the NO-FH group (50% vs 34%; P< .01). In multivariate logistic regression analysis, WM-FH was associated with higher odds of BNS (odds ratio [OR], 3.90; P = .005) and lower odds of neuropathy (OR, 0.49; P = .03) than NO-FH. The median TTFT was 0.7 years, OS was 23 years, and SAFTI was 20.5 years for all patients. In multivariate Cox regression analyses, WM-FH did not affect TTFT, SAFTI, or OS. Our study suggests higher odds of BNS and lower odds of neuropathy in patients with WM-FH but no impact of WM-FH on TTFT, OS, or SAFTI.
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Venetoclax is highly active in previously treated Waldenström macroglobulinemia (WM). However, data on the long-term durability and retreatment with venetoclax remain limited. Herein, we present an update of a prospective clinical trial of finite-duration venetoclax on 32 previously treated patients with WM. With a median follow-up of 81 months, 23 patients (72%) had disease progression, 17 (53%) began a new treatment, and 3 (9%) had died. The median progression-free survival (PFS) was 36 months, and the median treatment-free survival (TFS) was 43 months. PFS and TFS were superior in patients who attained at least a partial response to therapy. CXCR4 mutations or previous Bruton tyrosine kinase inhibitor exposure did not impact these outcomes. Of the 17 patients who started a new therapy after completion of venetoclax therapy, 9 were retreated with venetoclax alone or in combination with other treatments (3 attained a very good partial response, 4 attained a partial response, 1 had stable disease, and 1 did not respond). No BCL2 G101V mutations were detected in 52 CD19-selected bone marrow samples from 27 patients during treatment. Venetoclax induced durable responses in WM, thereby enabling retreatment in patients who progressed after completing therapy without the emergence of BCL2 G101V mutations. This trial was registered at www.ClinicalTrials.gov as #NCT02677324.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (32)
Simone FERRERO
University of Turin
sairah ahmed
Professor
The University of Texas MD Anderson Cancer Center
Stefan Barta
Academic Clinician Associate Professor
University of Pennsylvania
Shaji Kumar
Medical College of Wisconsin
Mehdi Hamadani
-
Ariela Noy
Memorial Sloan Kettering Cancer Center
Constantine S. Tam
-
Camille V Edwards
Assistant Professor of Medicine
Boston University School of Medicine
Peter Riedell
University of Chicago
Steven Treon
Professor
Harvard Medical School
Luis Malpica
Assistant Professor
The University of Texas MD Anderson Cancer Center
Julio Chavez
Associate Professor
Moffitt Cancer Center
Jorge Florindez
Johns Hopkins University
Adam Olszewski
Associate Professor of Medicine
Rhode Island Hospital
Judith Trotman
Head of Department
Concord Repatriation General Hospital
Sebastian Grosicki
Head of Department, MD PhD, Ass. Prof
Medical University of Silesia
Morie Gertz
Mayo Clinic
Shirong Liu
Senior Scientist
Dana-Farber Cancer Institute
Alain Delmer
Professor of Hematology
-
Angela Dispenzieri
Professor / Consultant
Mayo Clinic Minnesota
Stephen Opat
Monash Health
Mehmet Samur
Senior Research Scientist
Dana-Farber Cancer Institute
Carlos Fernandez de Larrea Rodriguez
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Michele Bibas
Chief of Hematology Service
-
Ramón García-Sanz
Profesor Titular de Medicina / Hematología
Universidad Complutense de Madrid
Ranjana Advani
Saul A. Rosenberg Professor of Lymphoma
-
Monique C. Minnema
-
Tanya Siddiqi
Associate Professor
City Of Hope National Medical Center
Roch Houot
university hospital of Rennes
Jonas Paludo
Assistant Professor of Medicine and Oncology
Mayo Clinic
Timothy Voorhees
Associate Professor of Clinical Internal Medicine
The Ohio State University Wexner Medical Center
Ari M. Melnick
Director
Josep Carreras Leukaemia Research Institute
Make your next move.
Prepare your application
Review drafts before you send them.